Earnings Presentation for the Quarter ended June 30, 2026

August 08, 2026 BSE Limited National Stock Exchange of India Limited P. J. Towers, Exchange Plaza, Plot No. C/1, Dalal Street, G Block, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E) Mumbai- 400 051 Scrip Code-540025 Trading Symbol-ADVENZYMES Subject: Earnings Presentation Ref: ISIN: INE837H01020 Dear Sir/Madam, Pursuant to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed is the Earnings Presentation for the quarter ended June 30, 2026. This is for your information and for public at large. Thanking you, Yours faithfully, For Advanced Enzyme Technologies Limited Sanjay Basantani Company Secretary and Head – Legal Encl.: As above Advanced Enzyme Technologies Limited Earnings Presentation August 2026 Safe Harbour Statement This presentation contains forward-looking statements that reflect management’s current views with respect to certain future events and potential financial performance. Forward-looking statements are other than statements of historical facts. The words “believe,”“expect,”“anticipate,” “intend,”“estimate,”“outlook,” “will,”“may,”“continue,”“should”and similar expressions identify forward-looking statements. Forward-looking statements include statements regarding objectives, goals, strategies, outlook and growth prospects; future plans, events or performance and potential for future growth; liquidity, capital resources and capital expenditures; economic outlook and industry trends; developments of the Company’s markets; the impact of regulatory initiatives; and the strength of competitors. The forward-looking statements in this presentation are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management’s examination of historical operating trends, data contained in records and other data available from third parties. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and maybe beyond our control. Such risks, uncertainties, contingencies and other important factors could cause the actual results of the Company or the industry to differ materially from those results expressed or implied in this presentation by such forward-looking statements. The information, opinions and forward-looking statements contained in this presentation speak only as at the date of this presentation and are subject to change without notice. The Company and its respective agents, employees or advisors do not intend to, and expressly disclaim any duty, undertaking or obligation to, make or disseminate any supplement, amendment, update or revision to any of the information, opinions or forward-looking statements contained in this presentation to reflect any change in events, conditions or circumstances beyond what is required by applicable law or applicable stock exchange rules and regulations. By viewing this presentation, you acknowledge and agree to be bound by the foregoing limitations and restrictions. EarningsPresentation | August 2026 Performance Business 01 02 Summary | Q1 FY27 | Page 04 Performance | Page 06 Geographical Result 03 04 Performance | Page 10 Summary | Q1 FY27 | Page 11 Unique Focus Area 05 06 Investment Case | Page 25 Going Ahead | Page 29 TABLE OF Shareholders’ Information | Page 30 CONTENTS EarningsPresentation | August 2026 Results Summary – Q1 FY27 (Consolidated) Y-o-Y Revenue (`mn) EBITDA (`mn) PAT (`mn) 1,859 1,898 564 510 386 2 10 5 % % % Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Q1 FY26 Q1 FY27 Revenue grew by 2% on y-o-y basis to EBITDA de-grew by 10% to ₹ 510 million PAT decreased to ₹ 386 million in Q1 FY27 EBITDA margin and PAT margin during Q1 ₹ 1,898million in Q1 FY27 from in Q1 FY27 as against ₹ 564 million from ₹ 404 million in Q1 FY26, decline of 5% FY27 stands at 27% and 20% respectively ₹ 1,859 million in Q1 FY26 in Q1 FY26 on y-o-y basis on y-o-y basis Notes: 1. On Consolidated Basis 2. PAT is before minority 3. Ind AS adjustments are carried out on account of commission, discount. And provision for sales return EarningsPresentation | August 2026 Results Summary – Q1 FY27 (Consolidated) Q-o-Q Revenue (` mn) EBITDA (`mn) PAT (`mn) 2,034 632 1,898 510 386 7 19 15 % % % Q4 FY26 Q1 FY27 Q4 FY26 Q1 FY27 Q4 FY26 Q1 FY27 Revenue de-grew by 7% on q-o-q basis to EBITDA de-grew by 19% to ₹ 510 million in Q1 PAT decreased to ₹ 386 million in Q1 FY27 ₹ 1,898 million in Q1 FY27 from ₹ 2,034 million FY27 as against ₹ 632 million in Q4 FY26 on from ₹ 453 million in Q4 FY26, de-growth in Q4 FY26 sequential basis of 15% on q-o-q basis Notes: 1. On Consolidated Basis 2. PAT is before minority 3. Ind AS adjustments are carried out on account of commission, discount. And provision for sales return EarningsPresentation | August 2026 Human Nutrition (₹in Million) Q1FY27 Q1 FY26 1,139 1,221 of Sales Commentary: 1,221 1,212 1,281 1,139 • The human nutrition segment contributed 1,012 992 1,018 1,031 around 60% during the quarter to the total revenue from operations • This segment de-grew by 7% during the quarter from ₹ 1,221 million in Q1 FY26 to ₹ 1,139 million in Q1 FY27 and it de-grew by 11% on sequential basis Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Notes: All the decimals are rounded off to their relevant nearest number EarningsPresentation | August 2026 Animal Nutrition (₹in Million) Q1FY27 Q1 FY26 252 260 of Sales Commentary: 244 250 252 • The animal nutrition segment contributed around 13% during the quarter to the total 197 193 revenue from operations 172 • This segment de-grew by 3% during the quarter from ₹ 260 million in Q1 FY26 to ₹ 252 million in Q1 FY27 and it grew by 1% on sequential basis Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Notes: All the decimals are rounded off to their relevant nearest number EarningsPresentation | August 2026 7 Industrial Bio-processing (₹in Million) Food Q1FY27 Q1 FY26 Q1 FY27: ₹ 263 Mn +30% 306 236 of Sales Non-Food Q1 FY27: ₹ 43 Mn Commentary: 321 324 • The Industrial Bio-Processing segment contributed around 16% during the quarter to the total revenue 251 255 from operations • This segment grew by 30% on y-o-y basis to ₹ 306 million in Q1 FY27 from ₹ 236 million in Q1 FY26 and on q-o-q basis it de-grew by 5% • In this segment, food business grew by 51% to ₹ 263 million on y-o-y basis during Q1 FY27 and de- grew 5% on sequential basis. The Non-Food business stood at ₹ 43 million during the quarter and it de-grew Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 by 30% on y-o-y basis and 8% on sequential basis Notes: All the decimals are rounded off to their relevant nearest number EarningsPresentation | August 2026 8 Specialized Manufacturing (₹in Million) Q1FY27 Q1 FY26 +41% 200 142 of Sales Commentary: • This segment contributed about 11% during 185 180 the quarter to the total revenue from 154 154 155 operations 142 • This segment outperformed by 41% on y-o-y 110 basis at ₹ 200 million in Q1 FY27, and 11% on q-o-q basis Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Notes: All the decimals are rounded off to their relevant nearest number EarningsPresentation | August 2026 9 Geographical performance (₹in Million) Q1 FY27 937 India 49% -4% Q1 FY26 979 Q1 FY27 546 Americas 29% -3% Q1 FY26 565 Q1 FY27 132 Europe 7% +44% Q1 FY26 92 Q1 FY27 242 Asia* 13% +37% Q1 FY26 177 Q1 FY27 40 Rest of the World 2% -15% Q1 FY26 47 Notes: 1. All the decimals are rounded off to their relevant nearest number 2. *Asia is excluding India EarningsPresentation | August 2026 10 Profit & Loss (Consolidated) – Q1 FY27 (₹in Million) Q1 FY27 Q4 FY26 Q1 FY26 Y-o-Y Q-o-Q FY26 FY25 Y-o-Y Particulars Un-Audited Audited Un-Audited (%) (%) Audited Audited (%) Income from O [Showing first 8,000 characters — download PDF for full document]